Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E33.22 EPS (ttm)3.73 Insider Own0.10% Shs Outstand220.60M Perf Week0.20%
Market Cap26.72B Forward P/E9.91 EPS next Y12.51 Insider Trans-3.08% Shs Float218.43M Perf Month10.97%
Income846.10M PEG2.70 EPS next Q2.58 Inst Own93.90% Short Float2.56% Perf Quarter17.11%
Sales5.54B P/S4.83 EPS this Y6.90% Inst Trans0.18% Short Ratio2.64 Perf Half Y19.33%
Book/sh47.56 P/B2.61 EPS next Y11.08% ROA5.00% Target Price143.28 Perf Year23.10%
Cash/sh13.24 P/C9.37 EPS next 5Y12.32% ROE7.70% 52W Range72.67 - 128.57 Perf YTD14.66%
Dividend- P/FCF11.29 EPS past 5Y26.80% ROI16.90% 52W High-3.55% Beta1.34
Dividend %- Quick Ratio4.30 Sales past 5Y17.40% Gross Margin91.60% 52W Low70.63% ATR4.37
Employees3082 Current Ratio4.80 Sales Q/Q20.10% Oper. Margin7.20% RSI (14)62.90 Volatility2.90% 3.41%
OptionableYes Debt/Eq0.23 EPS Q/Q-337.60% Profit Margin15.30% Rel Volume0.78 Prev Close121.76
ShortableYes LT Debt/Eq0.22 EarningsJul 30 BMO Payout0.00% Avg Volume2.12M Price124.00
Recom2.10 SMA204.92% SMA5011.10% SMA20017.91% Volume1,645,511 Change1.84%
Sep-01-20Resumed Stifel Hold $120 → $117
Jul-31-20Downgrade William Blair Outperform → Mkt Perform
Apr-28-20Initiated Cantor Fitzgerald Neutral $121
Mar-17-20Downgrade Oppenheimer Outperform → Perform
Mar-05-20Downgrade BofA/Merrill Buy → Neutral $130 → $110
Jan-31-20Resumed RBC Capital Mkts Outperform $135
Dec-17-19Downgrade Morgan Stanley Overweight → Equal-Weight $170 → $128
Nov-12-19Initiated SunTrust Buy $125
Oct-17-19Resumed BofA/Merrill Buy $130
Sep-26-19Initiated William Blair Outperform
Jul-31-19Resumed JP Morgan Overweight $172
May-23-19Resumed Goldman Neutral $142
May-23-19Resumed Citigroup Buy
May-23-19Initiated Wedbush Outperform
Apr-10-19Resumed Raymond James Outperform $161
Mar-27-19Reiterated RBC Capital Mkts Outperform $165 → $186
Mar-21-19Reiterated Guggenheim Neutral $135
Feb-22-19Initiated Guggenheim Neutral $135
Aug-07-18Downgrade Stifel Buy → Hold $154 → $130
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Oct-20-20 04:30PM  
Oct-16-20 12:07PM  
06:19AM  
Oct-15-20 07:03AM  
Oct-13-20 10:30AM  
Oct-12-20 08:30AM  
Oct-11-20 06:36AM  
Oct-09-20 02:00PM  
12:10PM  
11:23AM  
Oct-08-20 08:37AM  
08:14AM  
05:39AM  
Oct-07-20 01:04PM  
10:39AM  
10:34AM  
07:21AM  
Oct-06-20 04:24PM  
09:46AM  
08:47AM  
06:47AM  
06:30AM  
Oct-05-20 09:58AM  
07:49AM  
06:06AM  
Oct-04-20 07:15AM  
Oct-03-20 08:38AM  
Oct-02-20 08:33PM  
Sep-28-20 03:03PM  
Sep-27-20 06:12AM  
Sep-25-20 08:30AM  
Sep-24-20 02:56PM  
Sep-22-20 09:56AM  
Sep-21-20 02:00AM  
Sep-16-20 06:27AM  
Sep-15-20 10:09AM  
Sep-14-20 11:32AM  
08:00AM  
07:00AM  
Sep-09-20 08:30AM  
Sep-04-20 05:50PM  
04:45PM  
Sep-03-20 06:30AM  
Sep-02-20 03:58PM  
12:56PM  
Sep-01-20 08:37AM  
Aug-31-20 02:53PM  
01:33PM  
Aug-29-20 11:31AM  
Aug-24-20 01:12PM  
Aug-17-20 10:07AM  
Aug-06-20 08:00AM  
Aug-05-20 10:05AM  
Jul-31-20 07:31AM  
05:51AM  
Jul-30-20 07:32PM  
12:00PM  
11:14AM  
10:55AM  
07:50AM  
06:30AM  
Jul-29-20 08:27AM  
Jul-27-20 06:07PM  
03:25PM  
Jul-24-20 01:13PM  
Jul-23-20 12:32PM  
Jul-19-20 11:54AM  
Jul-16-20 06:30AM  
Jul-15-20 12:31PM  
Jul-14-20 01:11PM  
Jul-13-20 11:25AM  
Jul-08-20 01:21PM  
Jul-07-20 06:48PM  
10:00AM  
Jul-06-20 09:06AM  
Jul-02-20 12:10PM  
09:12AM  
08:48AM  
08:45AM  
Jul-01-20 09:43AM  
Jun-30-20 02:34PM  
Jun-29-20 02:00AM  
Jun-26-20 10:37AM  
Jun-25-20 12:18PM  
10:50AM  
Jun-24-20 09:12AM  
Jun-23-20 10:24AM  
Jun-17-20 08:30AM  
06:30AM  
05:51AM  
Jun-13-20 04:22PM  
Jun-12-20 10:09AM  
08:45AM  
08:20AM  
Jun-11-20 10:36PM  
11:10AM  
Jun-10-20 05:51AM  
Jun-09-20 01:51PM  
Jun-08-20 02:48PM  
12:29PM  
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Franchini Indrani LallEVP, Chief Compliance OfficerJun 08Sale114.696,853785,98128,218Jun 09 05:05 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy82.0181,3796,673,9357,841,556Mar 18 06:46 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy79.7650,9024,059,7927,766,918Mar 18 06:45 PM
BAKER BROS. ADVISORS LPDirectorMar 17Buy76.51102,4217,836,5857,720,234Mar 18 06:45 PM
BAKER BROS. ADVISORS LPDirectorMar 16Buy78.76265,29820,894,7537,626,298Mar 18 06:45 PM